Authors

  • Хамраев Б.Ж., Хамидова Ф.М.

Keywords:

муковисцидоз, CFTR, бронхоэктазия, дети, морфология, молекулярно-генетическая диагностика, реактивные изменения.

References

1. Mehdizadeh Hakkak A., Keramatipour M., Talebi S., Brook A., Tavakol Afshari J., Raazi A. Molecular analysis of the CFTR gene in Iranian cystic fibrosis patients // Iranian Journal of Basic Medical Sciences.

— 2013. — Vol. 16, № 8. — P. 917–921.

2. Boboniyazov I., Khamidova F.M., Khamraev B.J. Modern aspects of molecular genetic diagnosis of cystic fibrosis in children // Journal of Biomedicine and Practice. — 2024. — Vol. 9, № 2. — P. 45–51.

3. Эседов Э.М., Кондратьева Е.И., Шерман В.Д. Муковисцидоз у детей: современные представления о патогенезе, диагностике и лечении // Педиатрия. — 2016. — Т. 95, № 4. — С. 112–118.

4. Ratjen F., Bell S.C., Rowe S.M., Goss C.H., Quittner A.L., Bush A. Cystic fibrosis // Nature Reviews Disease Primers. — 2015. — Vol. 1. — Article ID 15010.

5. Elborn J.S. Cystic fibrosis // The Lancet. — 2016. — Vol. 388, № 10059. — P. 2519–2531.

6. Mall M.A., Hartl D. CFTR: cystic fibrosis and beyond // European Respiratory Journal. — 2014. — Vol. 44, № 4. — P. 1042–1054.

7. Stoltz D.A., Meyerholz D.K., Welsh M.J. Origins of cystic fibrosis lung disease // New England Journal of Medicine. — 2015. — Vol. 372, № 4. — P. 351–362.

8. Boucher R.C. Muco-obstructive lung diseases // New England Journal of Medicine. — 2019. — Vol. 380,

№ 20. — P. 1941–1953.

9. Cantin A.M., Hartl D., Konstan M.W., Chmiel J.F. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy // Journal of Cystic Fibrosis. — 2015. — Vol. 14, № 4. — P. 419–430.

10. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis // American Journal of Respiratory and Critical Care Medicine. — 2003. — Vol. 168, № 8. — P. 918–951.

11. Полшведкина О.Б., Скачкова М.А., Кондратьева Е.И. Клинические особенности бронхолёгочного поражения при муковисцидозе у детей // Российский педиатрический журнал. — 2017. — Т. 20, № 5. — С. 276–281.

12. Flume P.A., Mogayzel P.J., Robinson K.A., et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations // American Journal of Respiratory and Critical Care Medicine. — 2009. — Vol. 180, № 9. — P. 802–808.

13. Regamey N., Jeffery P.K., Alton E.W., et al. Airway remodelling and its relationship to inflammation in cystic fibrosis // Thorax. — 2011. — Vol. 66, № 7. — P. 624–629.

14. Hays S.R., Fahy J.V. Characterizing mucous cell remodeling in cystic fibrosis // American Journal of Respiratory and Critical Care Medicine. — 2006. — Vol. 174, № 9. — P. 1018–1024.

15. Kapur N., Masters I.B., Chang A.B. Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis // Chest. — 2010. — Vol. 138, № 1. — P. 158–164.

16. Chalmers J.D., Chang A.B., Chotirmall S.H., Dhar R., McShane P.J. Bronchiectasis // Nature Reviews Disease Primers. — 2018. — Vol. 4. — Article ID 45.

17. Pier G.B., Grout M., Zaidi T.S. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung // Proceedings of the National Academy of Sciences USA. — 1997. — Vol. 94, № 22. — P. 12088–12093.

18. Darling K.E.A., Evans T.J. Effects of Pseudomonas aeruginosa infection on cystic fibrosis airway inflammation // Future Microbiology. — 2017. — Vol. 12, № 12. — P. 1067–1079.

19. Cohen T.S., Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome // Nature Medicine. — 2012.

— Vol. 18, № 4. — P. 509–519.

20. Chang A.B., Bush A., Grimwood K. Bronchiectasis in children: diagnosis and treatment // The Lancet. — 2018. — Vol. 392, № 10150. — P. 866–879.

21. Pasteur M.C., Bilton D., Hill A.T. British Thoracic Society guideline for non-CF bronchiectasis // Thorax.

— 2010. — Vol. 65, Suppl. 1. — P. i1–i58.

22. Cutting G.R. Cystic fibrosis genetics: from molecular understanding to clinical application // Nature Reviews Genetics. — 2015. — Vol. 16, № 1. — P. 45–56.

23. Castellani C., Cuppens H., Macek M. Jr., et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice // Journal of Cystic Fibrosis. — 2008. — Vol. 7, № 3. — P. 179– 196.

24. McGarry M.E., McColley S.A. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype // Pediatric Pulmonology. — 2021. — Vol. 56, № 6. — P. 1496–1503.

25. Баратаева М.Б., Рахмонова А.А. Клинические и диагностические особенности муковисцидоза у новорождённых в Узбекистане // Вестник врача. — 2024. — № 2. — С. 38–43.

26. Farrell P.M., White T.B., Ren C.L., et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation // Journal of Pediatrics. — 2017. — Vol. 181S. — P. S4–S15.

27. De Boeck K., Amaral M.D. Progress in therapies for cystic fibrosis // The Lancet Respiratory Medicine.

— 2016. — Vol. 4, № 8. — P. 662–674.

28. Кондратьева Е.И., Красовский С.А., Амелина Е.Л., Шерман В.Д. Муковисцидоз: клинические рекомендации, диагностика и лечение. — Москва: Медпрактика-М, 2021. — 160 с.